Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Up 5.2%

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) rose 5.2% during trading on Monday . The company traded as high as $9.54 and last traded at $9.31. Approximately 869,843 shares were traded during trading, a decline of 85% from the average daily volume of 5,907,404 shares. The stock had previously closed at $8.85.

Analyst Ratings Changes

A number of brokerages have recently issued reports on RXRX. KeyCorp increased their price objective on shares of Recursion Pharmaceuticals from $15.00 to $16.00 and gave the stock an “overweight” rating in a research note on Monday, March 4th. Needham & Company LLC reiterated a “buy” rating and issued a $17.00 price target on shares of Recursion Pharmaceuticals in a research note on Tuesday.

Recursion Pharmaceuticals Trading Up 0.4 %

The business’s fifty day simple moving average is $8.81 and its 200-day simple moving average is $9.94.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its earnings results on Thursday, May 9th. The company reported ($0.39) EPS for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.04. The company had revenue of $13.80 million for the quarter, compared to the consensus estimate of $11.10 million. Recursion Pharmaceuticals had a negative return on equity of 79.96% and a negative net margin of 765.90%. The firm’s revenue for the quarter was up 14.0% on a year-over-year basis. During the same period in the previous year, the business earned ($0.34) earnings per share. As a group, equities research analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.6 earnings per share for the current year.

Insider Activity at Recursion Pharmaceuticals

In other Recursion Pharmaceuticals news, COO Tina Marriott sold 3,000 shares of Recursion Pharmaceuticals stock in a transaction on Thursday, May 30th. The shares were sold at an average price of $8.78, for a total value of $26,340.00. Following the completion of the transaction, the chief operating officer now directly owns 535,457 shares of the company’s stock, valued at approximately $4,701,312.46. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other news, COO Tina Marriott sold 3,000 shares of the firm’s stock in a transaction that occurred on Thursday, May 30th. The stock was sold at an average price of $8.78, for a total value of $26,340.00. Following the completion of the sale, the chief operating officer now directly owns 535,457 shares of the company’s stock, valued at approximately $4,701,312.46. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Michael Secora sold 15,000 shares of Recursion Pharmaceuticals stock in a transaction that occurred on Thursday, June 13th. The stock was sold at an average price of $9.32, for a total value of $139,800.00. Following the completion of the transaction, the chief financial officer now owns 1,243,468 shares of the company’s stock, valued at approximately $11,589,121.76. The disclosure for this sale can be found here. Insiders have sold a total of 281,359 shares of company stock valued at $2,410,876 over the last 90 days. 15.75% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Recursion Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Janney Montgomery Scott LLC bought a new position in Recursion Pharmaceuticals during the 3rd quarter valued at about $117,000. Charles Schwab Investment Management Inc. grew its stake in shares of Recursion Pharmaceuticals by 15.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,157,966 shares of the company’s stock valued at $8,858,000 after buying an additional 157,189 shares during the last quarter. UBS Group AG raised its holdings in shares of Recursion Pharmaceuticals by 103.1% in the third quarter. UBS Group AG now owns 342,679 shares of the company’s stock worth $2,621,000 after buying an additional 173,954 shares during the period. Deutsche Bank AG lifted its stake in shares of Recursion Pharmaceuticals by 15.4% during the 3rd quarter. Deutsche Bank AG now owns 59,688 shares of the company’s stock worth $457,000 after acquiring an additional 7,973 shares during the last quarter. Finally, QRG Capital Management Inc. bought a new position in Recursion Pharmaceuticals in the 3rd quarter valued at $86,000. Hedge funds and other institutional investors own 89.06% of the company’s stock.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.